Relief Therapeutics (OTC: RLFTF) is making big moves again, the company continues to impress investors with progress of their lead candidate, RLF-100 for Respiratory Illness in COVID-19 patients.
Relief Therapeutics & NeuroRx today announced topline results under U.S Expanded Access Protocol Authorization from 45 patients assessed in an open-label prospective study where 21 patients admitted to an intensive care unit (ICU) with critical COVID-19 and respiratory failure were treated with RLF-100™(aviptadil) and compared to 24 control patients treated in the same setting.
All patients had severe comorbidities that rendered them ineligible for the ongoing randomized controlled phase 2b/3 trial being conducted to ascertain safety and efficacy of RLF-100™, and all patients were deteriorating despite treatment with approved therapies for COVID-19.
Overall, 81% of RLF-100™-treated patients survived beyond 60 days, compared to 17% of control patients. Patients treated with RLF-100™ demonstrated a 9-fold increased probability of survival and recovery from respiratory failure, with a high degree of statistical significance. Statistical analysis was performed by Prof. Phil Lavin, FASA, FRAPS of the Boston Biostatistical Research Foundation.
Is Relief Therapeutics (OTC: RLFTF) a feasible investment?
Shares of Relief Therapeutics (OTC: RLFTF) appear to be a very good investment option, the Money Midnight Indicator is expecting its price to increase considerably in the next couple of months. The majority of the metrics point to this investment being highly attractive.